An interventional study of Single Task Exercise Training and Motor-Motor Dual Task Exercise Training in Parkinson's Disease (PD), sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.
Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 42nd largest by enrollment of the 99 interventional ones that give a count, is one of 29 that started in 2026, is one of 92 with no phase, and was the 158th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:
Mustafa Kemal University · Sites in Turkey
Ages 35–75 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 40+
Acibadem University · Sites in Turkey
Ages 40–85
Kahramanmaras Sutcu Imam University · Sites in Turkey
Ages 40–75
Medipol University · Sites in Turkey
Ages 50–80
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 32 across the 99 interventional studies, 61 across the 73 observational. Of the 104 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 172 have an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi is the lead sponsor of 458 studies on the registry; 124 are open to participants now.
Saglik Bilimleri Universitesi has 5 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
18 of the studies in Parkinson Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678983Izmir Bakircay UniversityWhole-Body Vibration in Parkinson Disease | 2026-12 |
| NCT06154356Karamanoğlu Mehmetbey UniversityAction Observation and Motor Imagery Therapy in Parkinson's Disease | 2026-12 |
| NCT07730073Atlas UniversityEfficacy of LSVT-LOUD Therapy on Voice, Speech, and Quality of Life in Parkinson's Disease | 2026-12 |
| NCT07010783Ankara UniversityRespiratory Functions in Parkinson's Disease | 2026-12-01 |
| NCT07641556Saglik Bilimleri UniversitesiThe Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease | 2026-12-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 172 studies in Parkinson Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare the effectiveness of motor-motor dual-task training and cognitive-motor dual-task training in patients with Parkinson's disease.The main questions it aims to answer are:
- Whether there is a difference between motor-motor dual-task training and cognitive-motor dual-task training in patients with Parkinson's disease in terms of their effects on motor symptoms, balance, gait, functional mobility, activities of daily living, dual-task activities, cognitive functions, and balance confidence.
Researchers will compare single-task training, motor-motor dual task training and cogvitive-motor dual task training.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single task balance and walking training
Other: Single Task Exercise Training
Motor-motor dual task balance and walking training
Other: Motor-Motor Dual Task Exercise Training
Cognitive-motor dual task balance and walking training
Other: Cognitive-Motor Dual Task Exercise Training
Single task balance and walking exercises. 5-minute warm-up period, followed by 15 minutes of balance exercises and 15 minutes of walking exercises with a 5-minute rest in between, and then a 5-minute cool-down period.
Motor-motor dual task balance and walking exercises. Motor-motor dual task balance and walking exercises. 5-minute warm-up period, followed by 15 minutes of balance exercises and 15 minutes of walking exercises concurrently performed with upper extremity motor tasks with a 5-minute rest in between, and then a 5-minute cool-down period.
Cognitive-motor dual task balance and walking exercises. Cognitive-motor dual task balance and walking exercises. 5-minute warm-up period, followed by 15 minutes of balance exercises and 15 minutes of walking exercises concurrently performed with cognitive tasks with a 5-minute rest in between, and then a 5-minute cool-down period.
Unified Parkinson's Disease Rating Scale (UPDRS) - PART 3
UPDRS is a reliable and valid scale that assesses cognitive skills, mood, daily living activities, motor skills, motor fluctuations, dyskinesias and autonomic dysfunction and is widely used in clinical studies and research in Parkinson's disease. The motor symptoms section, which is the third section of this scale, will be used.
Time frame: From enrollment to the end of training at 6 weeks
Hoehn & Yahr Scale
It is a staging system that provides information quickly in determining the severity and symptoms of Parkinson's disease.
Time frame: From enrollment to the end of treatment at 6 weeks
Single-Leg Stance Test
This is a test method used to assess static balance. The patient's preferred foot is raised without touching the supporting leg, and initially, the eyes are open. The eyes are fixed towards the head, and the patient is expected to maintain their balance for 60 seconds. The time the participant maintains their balance is recorded.
Time frame: From enrollment to the end of treatment at 6 weeks
Functional Reach Test
This test is designed to assess dynamic balance. In the test, the participant is positioned sideways next to a wall, with their torso upright, the shoulder on the wall flexed to 90°, and the elbow fully extended. The participant is then asked to make a fist with the same arm, and the position of the third metacarpal head is marked on the wall. The participant reaches forward with their knees fully extended; the position of the third metacarpal head is marked again, and the participant returns to the starting position. The difference between the two marks is measured with a tape measure.
Time frame: From enrollment to the end of treatment at 6 weeks
10 Meter Walking Test
Participants are asked to walk at normal walking speed for a distance of 10 meters and the time is recorded.
Time frame: From enrollment to the end of treatment at 6 weeks
Motor-Motor Dual Task Cost of Walking
To assess the motor-motor dual-task cost of walking, patients will perform the 10-meter walk test once as a single task and once while holding an empty plate on a tray in their hands. The dual-task cost will be calculated as a percentage using the following formula: \[(Dual-task performance - Single-task performance)/ (Single-task performance) x 100\]
Time frame: From enrollment to the end of treatment at 6 weeks
Cognitive-Motor Dual Task Cost of Walking
To assess cognitive-motor dual-task cost of walking, patients will perform the 10-Meter Walk Test once as a single task and once as a dual-task test, counting backwards in increments of 7 from a three-digit number greater than 300. Dual-task cost will be calculated as a percentage using the following formula: \[(Dual-task performance - Single-task performance)/ (Single-task performance) x 100\]
Time frame: From enrollment to the end of treatment at 6 weeks
Timed Up and Go Test
This test is used to assess functional mobility levels. The test involves using a standard chair with the individual's knees flexed at 90° and their backrest against it. The individual is asked to stand up from the chair, walk 3 meters, turn around, and then walk back to the chair and sit down. The test begins with the command "walk," and the test duration is measured with a stopwatch and recorded in seconds.
Time frame: From enrollment to the end of treatment at 6 weeks
Unified Parkinson's Disease Rating Scale (UPDRS) - PART 2
It consists of thirteen items. The assessment is based on anamnesis information regarding how the patient functions in various activities. The presence of sensory complaints that may be related to tremor and parkinsonism is also included in this section as they can affect daily living activities. Each item is evaluated using a scoring system between '0' and '4'.
Time frame: From enrollment to the end of treatment at 6 weeks
Dual Task Questionnaire
This test is used to assess the challenges encountered in daily tasks involving dual work. It consists of 10 questions and is administered via face-to-face interview. Each question is scored between 0 and 4. A score of "4" indicates frequent challenges, while a score of "0" indicates no challenges.
Time frame: From enrollment to the end of treatment at 6 weeks
Trail Making Test
It is used to assess executive functions and attention. The test consists of two parts, A and B. In part A, the individual is asked to combine numbers from 1 to 25, and the completion time is recorded. In part B, the individual completes a sequence where each number corresponds to a letter, and the completion time is recorded.
Time frame: From enrollment to the end of treatment at 6 weeks
Activity-Specific Balance Confidence Scale
This is a commonly used scale for assessing balance confidence. The scale evaluates whether individuals believe they can perform daily living activities without losing their balance or becoming unsteady. It consists of sixteen items. Each item is scored between a minimum of "0" (unconfident) and a maximum of "100" (completely confident). The base score is calculated by dividing the total score by 16. Higher values indicate that the person feels good about their balance, while lower values are associated with an increased risk of falls.
Time frame: From enrollment to the end of treatment at 6 weeks
Ran from Jun 2026 to primary completion in Oct 2026, 4 months.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 4 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi →